Congenital Dermatofibrosarcoma Protuberans

Orlando Oliveira de Morais, MD; Lisley Calixto de Araújo, MD; Ciro Martins Gomes, MD; Anglyia Samara Silva Leite Coutinho, MD; Fábio Augusto Albanez Souza, MD; Izelda Maria Carvalho Costa, PhD

Congenital dermatofibrosarcoma protuberans (DFSP) is a rare dermal and subcutaneous neoplasm of low-grade malignant behavior that is characterized by a low frequency of metastases with locally invasive growth. Its occurrence at birth and during childhood is rare. We present a case of a patient who was born with a light brown macule on his right buttock that was misdiagnosed as localized scleroderma. The lesion progressed into reddish atrophic plaques and nodules extending to the iliac region and the gluteal fold. At 5 years of age, a diagnosis of congenital DFSP was made based on clinical and immunohistochemical characteristics (CD34 positivity and spindle cell proliferation). Although there was a delay in diagnosis, a 3-step excision was proposed with a final step of Mohs micrographic surgery (MMS).


Case Report

A 5-year-old boy with a clinical history of a light brown macule on his right buttock that was present since birth was initially diagnosed with localized scleroderma after the lesion had steadily grown into an atrophic plaque during his first year of life. He was treated with calcipotriene–betamethasone dipropionate ointment and disease regression appeared to have been established until he was 4 years of age. At that time, new nodules started to arise on the lesion surface, leading the child’s guardians to seek medical attention.

Clinical examination revealed reddish plaques with irregular borders that were atrophic on palpation and extended from his right buttock to the iliac region and gluteal fold. Two reddish, painful, large, round nodules were seen on the lesion surface (Figure 1). A family history was not remarkable.

An incision biopsy showed a proliferation of spindle cells organized in a storiform pattern,

Figure 1. Erythematous reddish macules and confluent plaques on the right buttock extending to the iliac region and gluteal fold with a close-up of one of the larger lesions (inset).
extending from the papillary dermis to the hypodermis (Figure 2A). Immunohistochemistry was positive for CD34 (Figure 2B) and Ki-67 markers extending from the papillary dermis to the hypodermis (Figure 2A). Immunohistochemistry was positive for CD34 (Figure 2B) and Ki-67 markers.
and negative for S-100, desmin, pan-cytokeratin, neuron-specific enolase, and α smooth muscle actin.

Based on clinical, histologic, and immunohistochemical data, a diagnosis of congenital dermatofibrosarcoma protuberans (DFSP) was made. Because of the wide extension of the lesion, a 3-step excision was proposed with a final step of Mohs micrographic surgery (MMS)(Figure 3).

Comment

Dermatofibrosarcoma protuberans is a rare dermal and subcutaneous neoplasm that can be acquired or congenital in origin.1,2 Its occurrence at birth and during childhood is rare with approximately 60 congenital cases reported. In adults, its incidence is 0.8 to 5 cases per million, occurring mainly during the third and fourth decades of life with an equal gender distribution.1,2

The dermatologic presentation of DFSP is heterogeneous. The lesion usually begins as a pink-, red-, yellow-, or flesh-colored plaque that indurates on palpation. It grows slowly but steadily, and it ultimately develops into an isolated or multilobular surface nodularity as the tumor growth progresses.1,3,4 The trunk (42%–72%) and proximal extremities (16%–30%) are the main sites involved in patients with congenital DFSP or in adults.1,3

The clinical diagnosis of congenital or infantile DFSP may be difficult, as it sometimes resembles a vascular malformation or a birthmark. Other differential diagnoses may include scleroderma, lymphoma, sarcoidosis, melanoma, cutaneous metastases, keloids, a desmoid tumor, fibrosarcoma, appendage tumors, and dermatofibromas.1,4

Histologically, DFSP consists of a proliferation of monomorphic spindle cells organized in a storiform pattern. More frequently the tumor adopts an asymmetric fashion with microscopic tentaclelike projections emanating from the center of the tumor at random, enabling it to extend between healthy collagen, adipose tissue, fascia, and muscle.5 Some of these characteristics were observed in our patient, with the lesion presenting several morphologic components and showing uninvolved skin tissue between patches and tumor nodules.

Although the histogenesis of DFSP is uncertain, histologic distinction between DFSP and dermatofibroma is important because their biologic behavior differs greatly. Immunohistochemical studies have been widely used to make the distinction. Dermatofibrosarcoma protuberans usually shows positivity for CD34 antigen and negativity for desmin, S-100, insulinlike growth factor–binding protein 7, and factor XIIIa.5 Nevertheless, the fibrosarcomatous transformation of DFSP usually increases the tumor proliferation index and leads to the loss of CD34 membrane expression, thereby worsening the prognosis, especially by its faster local progression and increased likelihood of lung metastasis.3

Tissue samples also may be used to establish the molecular diagnosis of DFSP using reverse transcriptase polymerase chain reaction or the fluorescence in situ hybridization assay. A translocation involving chromosomes 17 and 22 (t[17;22][q11;q11]) will lead to the fusion of the collagen type I α 1 gene, COL1A1 and the platelet-derived growth factor β polypeptide gene, PDGFB, determining the production of an anomalous fusion protein that is detected by diagnostic tests.6 The protein activates the PDGF receptor protein tyrosine kinase of tumor cells, acting continuously as an autocrine or paracrine growth factor.5

Treatment of DFSP usually is wide local excision (WLE) with margins of 3 cm or more of clinically uninvolved skin and underlying fascia to avoid local recurrence. However, MMS has been proposed to be the gold standard given its capacity of detecting subclinical projections of neoplastic cells in the surrounding tissue as well as its observed ability to preserve more tissue and lower recurrence rates.1,2,7,9 A review by Love et al7 of 61 cases of congenital DFSP showed a clearance rate of 75% in patients who were treated with WLE (46/61; average follow-up of 1.9 years) compared to a 100% clearance rate in patients who were treated with MMS (11/11; average follow-up of 4.3 years). Another review of patients with congenital DFSP (n = 5) and acquired infantile-type DFSP (n = 20) showed no relapse following treatment with MMS.7 Paradisi et al7 reported an average local recurrence rate of 20.7% (288/1394) for WLE compared with 1.3% (6/463) for MMS (relative risk, 15.9; 95% confidence interval, 7.2-35.5). To date, MMS seems to be the most effective treatment of DFSP, and whenever possible, the use of paraffin-embedded sections may be preferred versus frozen sections.1,2,7,9 A 3-step excision was proposed for our patient because of the lesion width. Because we aimed for a lower recurrence rate, we opted to perform the final step with MMS.

Imatinib mesylate, an orally active selective protein tyrosine kinase inhibitor against the PDGF receptor, has been approved by the US Food and Drug Administration for the treatment of unresectable, recurrent, and/or metastatic DFSP in adults. A study of 15 patients with locally advanced or initially inoperable and/or metastatic DFSP who were treated with imatinib mesylate for an average of 3.3 months before surgical excision showed a 2-year progression-free survival rate of 60% (9/15).10
Currently, imatinib mesylate has not been approved for use in patients younger than 18 years, though successful treatment in pediatric patients has been observed in case studies. Gooskens et al1 reported 3 patients (aged 14 years, 3 years, and 12 months) with recurrent and/or locally advanced or initially inoperable tumors who received imatinib mesylate; the aim was complete resectability. All 3 patients had a positive response with a tumor size reduction that allowed surgical resection with histologically tumor-free margins. Imatinib mesylate was maintained in patients who showed molecular screening that was positive for COL1A1-PDGFB gene transcripts in resection margins. A follow-up ranging from 6 months to 3.5 years showed no relapse.1

Conclusion
We emphasize the value of using histologic and immunohistochemical correlation as an auxiliary tool, especially with clinical presentation that encompasses differential diagnoses, to determine different treatments and a distinct prognosis. Furthermore, the surgical aspects of our patient with congenital DFSP highlight the knowledge of disease management and enhance the index of suspicion in the pediatric population.

REFERENCES